Erectile function recovery in patients after radical prostatectomy using platelet-rich plasma and extracorporeal shock wave therapy: pilot study.

Epifanova M1, Kostin A1, Gameeva E1, Artemenko S1, Gritskevich A1, Epifanov A2

Research Type

Clinical

Abstract Category

Male Sexual Dysfunction

Abstract 316
Transgender Health, Male Sexual Dysfunction, Urethra
Scientific Podium Short Oral Session 38
Friday 29th September 2023
16:52 - 17:00
Room 101
Rehabilitation Sexual Dysfunction Clinical Trial Male
1. Peoples Friendship University of Russia (RUDN University), 2. A.I. Yevdokimov Moscow State University of Medicine and Dentistry
Presenter
Links

Abstract

Hypothesis / aims of study
Rehabilitation of patients after radical prostatectomy (RPE) remains an important problem, since most men develop erectile dysfunction (ED) in the postoperative period, even taking into account nerve-sparing techniques. The aim of the study was to evaluate the safety and effectiveness of platelet-rich plasma (PRP) and extracorporeal shock wave therapy (ESWT) in the treatment of erectile dysfunction in patients after robot-assisted nerve-sparing radical prostatectomy.
Study design, materials and methods
The pilot study included 14 men who underwent one or two side robot-assisted nerve-sparing RPE more than 3 months ago, PSA total was less than 0.2 ng/ml 3 months or more after surgery in all men. The mean age was 57.8±6.2 years (49-72), the mean ED duration was 7.6±3.9  months  (3-16). Pathologic stage:  T1c - 2 (14.3%), T2a - 4 (28.6%), T2b - 2 (14.3%), T2c - 4 (28.6%), T3a - 1 (7.14%), T3b - 1 (7.14%). All patients receive 2 sessions. Session 1 included ESWT (Dornier Aries) per penile and PRP injections into penile, finally PRP was activated with ESWT, session 2 included ESWT per penile. Each ESWT sessions were comprised 5000 pulses (0.05-0.096 mJ/mm2) and 8-5 Hz of frequency. The patients were examined on 0 and 60 days of the research using IIEF-5, EHS, SEP, GAQ, D-PDU, IPSS, QOL, total serum testosterone. Inclusion criterias:  absence of metastases to distant organs and lymph nodes, IIEF-5 less than 21 points after RPE, PSV less than 30 cm/s and/or RI less than 0.8 according to the D-PDU after RPE, the presence of erections before RPE. The study was approved by Ethics Committee of the RUDN Medical Institute.
Results
No side effects were recorded. IIEF-5 increased from 9.86±6.02  (0-20) to 17.93±4.5  (11-24) (p<0.05). SEP increased from 1.93±1.49  (0-5) to 3.29±1.69 (2-5) (p=0.002). EHS  increased from 1  (IQR%, 1-2) to 3  (IQR%, 2-3) (p=0.002). IPSS c 5±3.46 (0-11) decreased to 3.21±2.75 (0-7) (p=0.007). QOL changed from 4.29±1.68 (1-6) to 4.43±1.6 (1-6) (p=0.58). According to D-PDU data, PSV along the left cavernous artery (CA) increased from 17.9 cm/s (IQR%, 14-20.2) to 26.3 cm/s (IQR%, 21.1-29.7) (p=0.001). RI on the left CA  increased from 0.85±0.14 (0.58-1) to 0.9±0.09 (0.77-1) (p=0.018). Total blood testosterone changed  from 15.79±3.52 nmol/L (9.2-20.83) to 16.31±3.84 nmol/L (10.9-23.4) (p=0.192). According to GAQ, 11 patients (78.5%) noted a positive effect of treatment.
Interpretation of results
There is a positive trend in relation to a significant improvement in erectile function in all patients according to validated questionnaires and D-PDU. The proposed treatment is a promising method of rehabilitation of men in this population.
Concluding message
The study continues on a larger sample of patients.
Disclosures
Funding n/a Clinical Trial Yes Public Registry No RCT No Subjects Human Ethics Committee Ethics Committee of the RUDN Medical Institute. Helsinki Yes Informed Consent Yes
Citation

Continence 7S1 (2023) 101033
DOI: 10.1016/j.cont.2023.101033

20/11/2024 07:48:00